Moody Aldrich Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Moody Aldrich Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-327	Closed	-$207K	–	197
2025 Q1	$207K	Buy	+327	New	+$225K	0.04%	162
2024 Q4	–	Sell	-271	Closed	-$285K	–	217
2024 Q3	$285K	Sell	271 -46	-15%	-$51.2K	0.05%	167
2024 Q2	$333K	Sell	317 -1,539	-83%	-$1.49M	0.06%	154
2024 Q1	$1.79M	Sell	1,856 -137	-7%	-$130K	0.3%	108
2023 Q4	$1.75M	Sell	1,993 -55	-3%	-$45.3K	0.31%	101
2023 Q3	$1.69M	Buy	+2,048	New	+$1.61M	0.32%	94

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Moody Aldrich Partners's REGN Position: Q2 2025 in Review

Moody Aldrich Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 327 shares — an estimated $207K sold.

Moody Aldrich Partners first reported a position in REGN in Q3 2023 and held it in 6 quarters. The position peaked at $1.79M in Q1 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Moody Aldrich Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Moody Aldrich Partners sold 327 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $207K.
Moody Aldrich Partners first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 6 quarters.
Moody Aldrich Partners's Regeneron Pharmaceuticals position peaked at $1.79M in Q1 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Moody Aldrich Partners's 13F filing for Q2 2025, filed 4 Aug 2025.